Recombinant murine growth hormone from E. coli inclusion bodies: Expression, high-pressure solubilization and refolding, and characterization of activity and structure

Biotechnology Progress

Volumn 26, Issue 3, 2010, Pages 743-749

  Fradkin, Amber Haynes ^a   Boand, Carl S ^a   Eisenberg, Stephen P ^b   Rosendahl, Mary S ^b   Randolph, Theodore W ^a  

^a UCB 450   (United States)

^b BaroFold Inc   (United States)

Author keywords

High hydrostatic pressure; Inclusion bodies; Protein refolding; Recombinant murine growth hormone; Solubilization

Indexed keywords

CIRCULAR DICHROISM; E. COLI; GRAM SCALE; GROWTH HORMONES; HIGH HYDROSTATIC PRESSURE; HIGH SOLUBILITY; IMMUNOGENICITY; INCLUSION BODIES; PROTEIN REFOLDING; PURIFICATION PROTOCOL; REFOLDING; SECONDARY AND TERTIARY STRUCTURES; THERAPEUTIC PROTEIN; UV SPECTROSCOPY;

CIRCULAR DICHROISM SPECTROSCOPY; DICHROISM; ESCHERICHIA COLI; HYDRAULICS; HYDRODYNAMICS; HYDROSTATIC PRESSURE; PURIFICATION; SOLUBILITY; ULTRAVIOLET SPECTROSCOPY;

PROTEINS;

GROWTH HORMONE; RECOMBINANT PROTEIN;

ANIMAL; ARTICLE; BIOSYNTHESIS; CELL INCLUSION; CHEMISTRY; CIRCULAR DICHROISM; ESCHERICHIA COLI; FERMENTATION; GEL CHROMATOGRAPHY; GENETICS; HYPOPHYSECTOMY; ION EXCHANGE CHROMATOGRAPHY; MALE; METABOLISM; MOUSE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN FOLDING; RAT; SOLUBILITY; SPRAGUE DAWLEY RAT;

ANIMALS; CHROMATOGRAPHY, GEL; CHROMATOGRAPHY, ION EXCHANGE; CIRCULAR DICHROISM; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ESCHERICHIA COLI; FERMENTATION; GROWTH HORMONE; HYPOPHYSECTOMY; INCLUSION BODIES; MALE; MICE; PROTEIN FOLDING; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; SOLUBILITY;

MURINAE; RATTUS;

EID: 77954707948     PISSN: 87567938     EISSN: 15206033     Source Type: Journal    
DOI: 10.1002/btpr.393     Document Type: Article

References (44)

1. Molina PE. Anterior pituitary gland. In: Endocrine Physiology, 2nd ed., Malley J, Greenberg L, and Davis K, editors. New York: McGraw-Hill; 2006, Chapter 3. pp. 45-68.
2. Okada S, Kopchick JJ. Biological effects of growth hormone and its antagonist. Trends Mol Med. 2001;7:126-132.
3. Kopchick JJ, Bellush LL, Coschigano KT. Transgenic models of growth hormone action. Annu Rev Nutr. 1999;19:437-461.
4. Shepard TH, Nielsen RL, Johnson ML, Bernstein N. Human growth hormone. AMA J Dis Child. 1960;99:74-80.
5. Raben MS. Treatment of a pituitary dwarf with human growth hormone. J Clin Endocrinol Metab. 1958;18:901-903.
6. Hutchings JJ, Escamilla RF, Deamer WC, Li CH. Metabolic changes produced by human growth hormone (Li) in a pituitary dwarf. J Clin Endocrinol Metab. 1959;19:759-769.
7. Beck JC. Primate growth hormone studies in man. Proc R Soc Med. 1959;52:1047-1048.
8. Hintz RL, Wilson DM, Finno J, Rosenfeld RG, Bennett A, Mcclellan B. Biosynthetic methionyl human growth hormone is biologically active in adult man. Lancet. 1982;1:1276-1279.
9. Takano K, Shizume K, Hizuka N, Hibi I, Kato K, Kohno H, Kondo T, Ogawa M, Okada Y, Sudo M, Suwa S, Takahara J. Treatment of idiopathic pituitary dwarfism with methionyl human growth-hormone. Endocrinol Jpn. 1983;30:523-527.
10. Ahangari G, Ostadali MR, Rabani A, Rashidian J, Sanati MH, Zarindast MR. Growth hormone antibodies formation in patients treated with recombinant human growth hormone. Int J Immunopathol Pharmacol. 2004;17:33-38.
11. Moore WV, Leppert P. Role of aggregated human growth-hormone (HGH) in development of antibodies to HGH. J Clin Endocrinol Metab. 1980;51:691-697.
12. Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther. 2002;24:1720-1740.
13. Braun A, Kwee L, Labow MA, Alsenz J. Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice. Pharm Res. 1997;14:1472-1478.
14. Rosenberg AS. Effects of protein aggregates: an immunologic perspective. AAPS J. 2006;8:E501-E507.
15. Schellekens H. Immunogenicity of therapeutic proteins. Nephrol Dial Transplant. 2003;18:1257-1259.
16. Wang W, Kelner DN. Correlation of rFVIII inactivation with aggregation in solution. Pharm Res. 2003;20:693-700.
17. LaMerie Business Intelligence. Human Growth Hormone (hGH)-Market and R&D Pipeline. Competitor Analysis. Barcelona: La Merie; 2008.
18. Bugelski PJ, Treacy G. Predictive power of preclinical studies of recombinant therapeutic proteins in animals for the immunogenicity humans. Curr Opin Mol Ther. 2004;6:10-16.
19. Palmiter RD, Brinster RL, Hammer RE, Trumbauer ME, Rosenfeld MG, Birnberg NC, Evans RM. Dramatic growth of mice that develop from eggs micro-injected with metallothioneinegrowth hormone fusion genes. Nature. 1982;300:611-615.
20. Fradkin AH, Carpenter JF, Randolph TW. Immunogenicity of aggregates of recombinant human growth hormone in mouse models. J Pharm Sci. 2009;98:3247-3264.
21. Kane JF, Hartley DL. Formation of recombinant protein inclusion-bodies in Escherichia coli. Trends Biotechnol. 1988;6:95-101.
22. Fischer BE. Renaturation of recombinant proteins produced as inclusion-bodies. Biotechnol Adv. 1994;12:89-101.
23. Jungbauer A, Kaar W. Current status of technical protein refolding. J Biotechnol. 2007;128:587-596.
24. Qoronfleh MW, Hesterberg LK, Seefeldt MB. Confronting highthroughput protein refolding using high pressure and solution screens. Protein Expr Purif. 2007;55:209-224.
25. Crisman RI, Randolph TW. Refolding of proteins from inclusion bodies is favored by a diminished hydrophobic effect at elevated pressures. Biotechnol Bioeng. 2009;102:483-492.
26. Whitmore L, Wallace BA. DICHROWEB, an online server for protein secondary structure analyses from circular dichroism spectroscopic data. Nucleic Acids Res. 2004;32:W668-W673.
27. Patra AK, Mukhopadhyay R, Mukhija R, Krishnan A, Garg LC, Panda AK. Optimization of inclusion body solubilization and renaturation of recombinant human growth hormone from Escherichia coli. Protein Expr Purif. 2000;18:182-192.
28. Singh SM, Sharma K. High throughput purification of recombinant human growth hormone using radial flow chromatography. Protein Expr Purif. 2009;68:54-59.
29. Sugimoto S, Yamaguchi K, Yokoo Y. Characterization of recombinant eel growth-hormone. J Chromatogr. 1991;547:131-144.
30. Bewley TA, Li CH. Circular-dichroism studies on human pituitary growth-hormone and ovine pituitary lactogenic hormone. Biochemistry. 1972;11:884.
31. Bewley TA, Li CH. Molecular-weight and circular-dichroism studies of bovine and ovine pituitary growth hormones. Biochemistry. 1972;11:927.
32. Research Models: CD IGS Rat Weight Chart. Charles River Laboratories, Inc.; 2008. http://www.criver.com/SiteCollection-Documents/rm_rm_c_CD_IGS_rat_weight_chart.pdf Accessed Nov. 11, 2008.
33. Sugimoto S, Yokoo Y. Purification of recombinant salmon growth-hormone expressed in Escherichia coli. Biotechnol Lett. 1991;13:389-394.
34. Sugimoto S, Yokoo Y, Inui Y, Hirano T. Large-scale purification and refolding of recombinant eel growth-hormone. Agric Biol Chem. 1991;55:1635-1637.
35. Gill JA, Sumpter JP, Donaldson EM, Dye HM, Souza L, Berg T, Wypych J, Langley K. Recombinant chicken and bovine growth-hormones accelerate growth in aquacultured juvenile pacific salmon Oncorhynchus kisutch. Biotechnology. 1985;3:643-646.
36. Langley KE, Berg TF, Strickland TW, Fenton DM, Boone TC, Wypych J. Recombinant-DNA-derived bovine growth-hormone from Escherichia coli. I. Demonstration that the hormone is expressed in reduced form, and isolation of the hormone in oxidized, native form. Eur J Biochem. 1987;163:313-321.
37. Saxena VP, Wetlaufe DB. Formation of 3-dimensional structure in proteins. I. Rapid nonenzymic reactivation of reduced lysozyme. Biochemistry. 1970;9:5015.
38. Epstein CJ, Goldberg RF. A study of factors influencing reactivation of reduced egg white lysozyme. J Biol Chem. 1963;238:1380.
39. Rudolph R, Zettlmeissl G, Jaenicke R. Reconstitution of lacticdehydrogenase-non-covalent aggregation vs reactivation. II. Reactivation of irreversibly denatured aggregates. Biochemistry. 1979;18:5572-5575.
40. Puri NK. Refolding of recombinant porcine growth-hormone in a reducing environment limits invitro aggregate formation. FEBS Lett. 1991;292:187-190.
41. Randolph TW, Carpenter JF, St. John R. High Pressure Refolding of Protein Aggregates and Inclusion Bodies. USA: University Technology Corporation;1999.
42. Chura-Chambi RM, Genova LA, Affonso R, Morganti L. Refolding of endostatin from inclusion bodies using high hydrostatic pressure. Anal Biochem. 2008;379:32-39.
43. St John RJ, Carpenter JF, Balny C, Randolph TW. High pressure refolding of recombinant human growth hormone from insoluble aggregates-structural transformations, kinetic barriers, and energetics. J Biol Chem. 2001;276:46856-46863.
44. St John RJ, Carpenter JF, Randolph TW. High pressure fosters protein refolding from aggregates at high concentrations. Proc Natl Acad Sci USA. 1999;96:13029-13033.